Anna Kaltenboeck says in The Pink Sheet: “I do think it’s important to say that PBMs play an important role, which is to negotiate prices and access to drugs. Other countries do this at the national level. We don’t have that mechanism, so if the aim is to continue to have PBMs fill that role, I do hope that the right incentives will exist to ensure that they can negotiate effectively with pharma companies.
Read More
Read More